Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06117540
PHASE2

A Study of WX390 in Patients With Advanced Solid Tumors

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.

Official title: An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2021-05-11

Completion Date

2026-06-12

Last Updated

2024-11-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

WX390

WX390 tablet, 1.1 mg once a day

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China